CoronaVarCL: Omicron or Trivalent Vaccine Booster vs CoronaVac in Chile

Phase 2, randomised, double-blind trial of trivalent influenza vaccine in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Pontificia Universidad Católica de Chile. Primary endpoints: Superiority in humoral immunogenicity of the neutralizing antibodies against the Delta and Omicron variants in response to a booster dose of the trivalent vaccine compared to CoronaVac® at 6 months, Superiority in humoral immunogenicity of neutralizing antibodies against the Omicron variant in response to a booster dose with the Omicron vaccine when compared with CoronaVac® at 6 months and 2 more. Started Nov 2022; status: completed.